Haleon Says it Hasn't Been Notified About Litigation on Zantac Drug

By Sabela Ojea

Haleon PLC said Friday that it hasn't been notified about potential negative implications of U.S. lawsuits against discontinued heartburn drug Zantac.

The consumer-healthcare business, which was spun out of GSK PLC and is partly owned by Pfizer Inc., said that it isn't a party to any of the Zantac claims and that it never marketed the drug in any form in the U.S.

GSK PLC added that the U.S. Food and Drug Administration and European Medicines Agency have concluded there is no evidence of a causal association between ranitidine therapy and the development of cancer.

"The overwhelming weight of the scientific evidence supports the conclusion that there is no increased cancer risk associated with the use of ranitidine. Suggestions to the contrary are therefore inconsistent with the science, and GSK will vigorously defend itself against all meritless claims alleging otherwise," GSK said.

Write to Sabela Ojea at [e-mail]; @sabelaojeaguix

(END) Dow Jones Newswires

08-12-22 0220ET